XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Must have received: antineoplastic treatment

Patients must have undergone 1 prior line of antineoplastic treatment

Cannot have received: XL092 (XL092)

Patients who have received previous treatment with XL092

Cannot have received: small-molecule kinase inhibitor

Patients who have received any type of small-molecule kinase inhibitor (including an investigational kinase inhibitor) within 14 days prior to study day 1 treatment

Cannot have received: tyrosine kinase inhibitor

Patients who have received > 2 prior tyrosine kinase inhibitor therapies

Cannot have received: chemotherapy

Exception: unless completed > 4 weeks prior to study day 1 and recovered from toxicity/complications

Patients who have had prior chemotherapy, or radiation therapy within 4 weeks prior to study day 1 unless they have recovered from their prior therapy (toxicity and/or complications) such that they now meet all other eligibility criteria

Cannot have received: radiation therapy

Exception: unless completed > 4 weeks prior to study day 1 and recovered from toxicity/complications; for bone metastasis, radiation therapy within 14 days prior to registration is excluded

Patients who have had prior chemotherapy, or radiation therapy within 4 weeks prior to study day 1 unless they have recovered from their prior therapy (toxicity and/or complications) such that they now meet all other eligibility criteria; Patients who have received radiation therapy for bone metastasis within 14 days prior to registration

Cannot have received: radionuclide therapy

Patients who have undergone systemic treatment with radionuclides within 6 weeks (42 days) before first dose of study treatment

Cannot have received: investigational agent

currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of treatment